# A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy

> **NCT05819866** · PHASE3 · RECRUITING · sponsor: **Minoryx Therapeutics, S.L.** · enrollment: 40 (estimated)

## Conditions studied

- Cerebral Adrenoleukodystrophy (cALD)

## Interventions

- **DRUG:** Leriglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05819866
- **Lead sponsor:** Minoryx Therapeutics, S.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-12
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05819866

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05819866, "A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05819866. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*